Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KHK4951 in Neovascular Age-Related Macular Degeneration
NCT06116890Phase 2Completed
- Sponsor
- Kyowa Kirin
- Start
- Jan 2024
- Primary completion
- Jun 2026
- Modality
- Nanoparticles, Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of KHK4951 in neovascular age-related macular degeneration (NVAMD) (3 arms), sponsored by Kyowa Kirin. Primary endpoint: Reduction of 15 or more letters in Best Corrected Visual Acuity at 44 weeks. Started Jan 2024; status: completed.
02
Drugs
KHK4951
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT06116890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06116890.